reports
Artificial Intelligence-Driven Predictive Medical Diagnostics Company ...
Artificial Intelligence-Driven Predictive Medical Diagnostics Company Spectral MD Announces Closing of Business Combination Company Renamed “Spectral AI, Ltd.” and Will Commence Trading on Nasdaq Global Market Under the Symbol “MDAI” Effective September 12, 2023 Overview: Spectral AI is the Only Publicly Listed, AI-Driven Predictive Medical Diagnostic Company Developing Technology that is Specifically Engineered to Provide Clinicians with an Objective and Immediate Assessment of a Wound’s Healing PotentialThe Company is Building on $130+ Million to Date of U.S. Government Contracts Suppor...
Spectral MD Holdings, Ltd. (“Spectral MD” or the “Company”) ISO 13485 ...
Spectral MD Holdings, Ltd. (“Spectral MD” or the “Company”) ISO 13485 Certification Received for AI-Driven DeepView® Wound Imaging System LONDON and DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces that it has received ISO 13485 certification for the manufacture and distribution of its AI-driven DeepView® Wound Imaging System which is designed to provide immediate, accurate, and binary wound treatment assessments f...
- Sacha Morris
Hybridan Small Cap Feast 10/08/2023
Dish of the day Joiners: No joiners today. Leavers: National Milk Records plc (AQSE: NMRP) has left the AQSE Growth Market. What’s cooking in the IPO kitchen?** Announced ITF 4 August: Tan Delta Systems plc, a Sheffield based Company intends to IPO on AIM. Tan Delta has developed an innovative and differentiated monitoring solution based on real time oil analysis and analytics that offers equipment operators enhanced insight into the maintenance status of their equipment and thus the ability to ...
- Colin Smith
Spectral MD - 1Q23 Results
As part of the business combination with Rosecliff Acquisition (Rosecliff) which was announced in April, inaugural quarterly reporting for Spectral MD has commenced, starting with results for 1Q23. Rosecliff has also recently published its full prospectus relating to the transaction which is expected to complete in 3Q23. Under the terms of the transaction, the current shareholders of Spectral MD are expected to own a pro-forma 81.6% of the resultant business, with a conditional pro-forma enterpr...
- Colin Smith
Spectral MD - $4m funding for DeepView SnapShot® M
Spectral MD has been awarded $4m for the further funding of its DeepView SnapShot® M handheld device under development for the US military. The funding is to be provided by the Medical Technology Enterprise Consortium. This award follows a total of $1.8m in funding already provided by the Defense Health Agency toward the development of a handheld device with similar capabilities to Spectral MD's cart based DeepView SnapShot® technology and continues Spectral MD's ongoing success in gaining US go...
- Colin Smith
Spectral MD - Combination with Rosecliff Acquisition
Spectral MD has announced a proposed business combination with Rosecliff Acquisition (Rosecliff), a blank cheque, Special Purpose Acquisition Company (SPAC). The transaction offers a potential multiple uplift to the current share price but will result in the combined business, to be renamed ‘Spectral AI', being listed solely on the Nasdaq market with the AIM listing to be cancelled. Spectral MD highlights a potential enterprise value of $170m, equivalent to approximately 101p per share, effectiv...
- Colin Smith
Spectral MD - Post FY22 Results Consensus Update
Spectral MD reported better than expected results for FY22 following which, the three covering brokers all updated their forecasts with one putting through a minor increase in share price target resulting in the tightly grouped average increasing to 162p from 160p with over 4x upside to the current share price. The most important post period highlight was the news that BARDA issued a Sources Sought Notice for Burn Wound Imaging Technologies for which Spectral MD's technology looks extremely well...
Hybridan Small Cap Feast - 27 Feb 23
27 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec...
- Colin Smith
- Oliver Juggins
Spectral MD - 1H22 Results Update - Sep 2022
Following an exciting update from SMD, which confirmed that the FY23 commercialisation of the DFU Application in the US remains on track: a significant milestone and would represent the company's first non-R&D-linked revenue stream. Solid progress was made across the Burns, DFU, and Handheld Applications in 1H22, with SMD hitting several key operating milestones, winning further BARDA funding (which, we believe, also signals an increasing probability of federal procurement contracts in future)...
- Oliver Juggins
Spectral MD - Initiation Note - JUL 22
Spectral MD is a specialist in predictive analytics for medical applications. It uses its proprietary camera to take multispectral pictures of wounds such as burns and diabetic foot ulcers and its proprietary AI algorithms to determine, on day-one and with accuracy levels far exceeding current standards, which parts of the injured tissue will heal using everyday care and which ones need immediate intervention, removing delays of up to 30 days for treatment decisions. SMD offers a disruptive tec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.